Company: DMAAR
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001213900-25-026240
Chunk: 396

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 4
Chunk 396
---
 direction. Mr. Worman’s prior
experience in senior finance and chief operating officer positions in corporate finance, fixed income and equity capital markets, wealth
management, investment management, strategic analysis, interdealer brokerage, and compliance underscore his ability to handle industry
segment and public company chief financial officer requirements. Mr. Worman earned a BS degree from Ramapo College of New Jersey
and an MBA from Fairleigh Dickinson University.

Catherine Do has served as a member of
our board of directors since January 2025. Dr. Do was trained as a medical doctor specializing in Public Health and Epidemiology
in France, with a keen interest in molecular epidemiology. Due to the absence of a joint PhD-MD program in France, she paused her residency
to earn a master’s in Biostatistics and Clinical Research and a PhD in Molecular Pharmacology. After spending a year at the French
Drug Agency (ANSM) as a pharmaco-epidemiologist, Dr. Do pursued her interest in molecular research, undertaking a post-doctoral fellowship
in genetics and epigenetics at Columbia University. From 2017 to 2022, she served as an assistant scientist at the Center for Discovery
and Innovation at Hackensack University Medical Center. In 2022, to further her expertise in chromatin architecture, she joined NYU Langone
Health as an Assistant Professor in Pathology focusing on chromatin architecture, underscoring her central role in the field of drug discovery.
Dr. Do earned a master’s in Biostatistics and Clinical Research and a PhD in Molecular Pharmacology at Paul Sabatier University
in Toulouse, France.

17

G. Sridhar Prasad has served as a member
of our board of directors since January 2025. Dr. Prasad joined Syrrx, Inc., a drug discovery company, in 2001, leading crystallography
efforts that led to the discovery of Nesina®, a drug to treat type 2 diabetes. At Merck & Co. Inc., he was a lead crystallographer
on key drug discovery programs, including those for schizophrenia, oncology and HIV-1 AIDS. Dr. Prasad co-founded Plex Pharmaceuticals
in 2009, which was acquired by Collidion, Inc. in 2017, and served as its Chief Scientific Officer from 2009 to 2022. Dr. Prasad
is the